Proxalutamide

DB16065InvestigationalSmall molecule

Proxalutamide is under investigation in clinical trial NCT03899467 (The Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer).

Mechanism: Proxalutamide is an antagonist at the androgen receptor which leads to inhibition of androgen-induced receptor activation and results in formation of inactive complexes that are not able to translocate to the nucleus. It also induces androgen receptor downregulation, furthering adrogen-induced receptor activation. This drug is being investigated for its potential antineoplastic activity and is being investigated specifically against prostate cancer and COVID-19.
Curator reviewed
Formula / weight: C₂₄H₁₉F₄N₅O₂S · 517.5 g/mol (avg)
Also known as: Pruxelutamide
Code names: GT-0918

Resolves to

Compound

UNIIQX6O64GP40CAS1398046-21-3

Structure

InChIKeyKCBJGVDOSBKVKP-UHFFFAOYSA-NSMILESCC1(C)N(C(=S)N(C1=O)C1=C(F)C(=C(C=C1)C#N)C(F)(F)F)C1=CN=C(CCCC2=NC=CO2)C=C1

Targets

P10275AR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Proxalutamide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account